Perineuronal net complex protein mRNA transcripts (PNN mRNA)

Perineuronal nets (PNNs) are specialized extracellular matrix (ECM) structures that encapsulate the cell bodies and proximal dendrites of specific neurons, most notably parvalbumin-positive (PV+) interneurons [1, 3]. These structures are composed of chondroitin sulfate proteoglycans (CSPGs) such as aggrecan and brevican, linked to a hyaluronan backbone via link proteins (HAPLN1/4) and stabilized by tenascin-R [1, 4]. The primary biological function of PNNs is to restrict synaptic plasticity and stabilize neural circuits following the closure of developmental critical periods [1, 5]. mRNA transcripts encoding these PNN complex proteins represent a novel therapeutic target class; by utilizing RNA interference (RNAi) or antisense oligonucleotides (ASOs) to knockdown these transcripts, it is possible to reduce PNN density and reopen windows of plasticity [2]. This approach is being explored for the treatment of neurological conditions where plasticity is impaired or where circuit rewiring is beneficial, such as spinal cord injury, stroke recovery, and Alzheimer's disease [1, 2, 5]. However, therapeutic modulation of PNN mRNA must be carefully managed, as excessive degradation of these structures can lead to neuronal hyperexcitability, increased seizure susceptibility, or the degradation of established long-term memories [1, 3].

Other names

PNN transcriptsmRNA of perineuronal net componentsExtracellular matrix mRNA in CNS

Reduction of PNN protein synthesis via RNA interference (RNAi) or antisense-mediated degradation of transcripts to decrease PNN density and restore synaptic plasticity.